A new study provides the first insights into epigenetic heterogeneity in AML. The study highlights a striking independence of genetic and epigenetic variation, and links the kinetics of epigenetic change to clinical outcome.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Marina Corral Spence/Nature Publishing Group
References
Greaves, M. Cancer Discov. 5, 806–820 (2015).
Ley, T.J. et al. N. Engl. J. Med. 368, 2059–2074 (2013).
Gawad, C., Koh, W. & Quake, S.R. Nat. Rev. Genet. 17, 175–188 (2016).
Marusyk, A., Almendro, V. & Polyak, K. Nat. Rev. Cancer 12, 323–334 (2012).
Grimwade, D., Ivey, A. & Huntly, B.J.P. Blood 127, 29–41 (2016).
Figueroa, M.E. et al. Cancer Cell 17, 13–27 (2010).
Li, S. et al. Nat. Med. 22, 792–799 (2016).
Li, S. et al. Genome Biol. 15, 472 (2014).
Pan, H. et al. Nat. Commun. 6, 6921 (2015).
Mazor, T. et al. Cancer Cell 28, 307–317 (2015).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Sasca, D., Huntly, B. Independence of epigenetic and genetic diversity in AML. Nat Med 22, 708–709 (2016). https://doi.org/10.1038/nm.4136
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.4136
